Two supplied papers anchor the pathway logic. In microglia, LPS-driven COX-2 mRNA/protein and PGE2 are suppressed by blocking the STAT1/3–GAS axis (Withaferin A), and COX-2 mRNA stability was unchanged, pointing to transcriptional control upstream of PGE2 . Separately, alpha7 nAChR activation (PNU-282987, 5–15 μM) reduced TNF-α/IL-1β/IL-6 mRNA, p-JAK2/p-STAT3, COX-2/mPGES-1 and PGE2, with MLA (5 μM) reversing the effect — the key epistasis logic to transplant into microglia . Rat primary microglia robustly upregulate COX-2/mPGES-1 and PGE2 after TLR stimulation, confirming the readout window (~12 h) works in primary cells .
Cells: primary microglia from neonatal rat cortex (within-paper-typical: 1-day-old Sprague–Dawley, as in the microglia COX-2 studies) . Factorial arms (2×2×2): (A) alpha7 state: vehicle / PNU-282987 (5–10 μM) with confirmatory MLA (5 μM) reversal; (B) inflammatory context: vehicle / IFN-γ (typical 10–20 ng/mL, 18–24 h priming); (C) PGE2 signal: vehicle / EP2 antagonist (AH6809) + EP4 antagonist (ONO-AE3-208 or L-161,982). Include LPS or poly(I:C) co-stimulation arm, since alpha7 effects above were demonstrated against a TLR trigger . Timepoints: 4 h (STAT1/3 phosphorylation, nuclear translocation), 6–8 h (COX-2/TNF/IL-10 mRNA), 12 h (COX-2 protein, PGE2 EIA — matching the 12 h peak used in both papers) .
The PGE2 paradox is real: in the alpha7 source study, PNU-282987 upregulated COX-2/PGE2 when COX-2 was pharmacologically blocked, showing PGE2's role is context-dependent . Additional blindspots: MLA off-target effects at higher doses are documented in nicotinic pharmacology ; use MLA + a second antagonist or alpha7 siRNA/Chrna7−/− microglia for confirmation. No supplied record reports TNF/IL-10 polarity or migration under combined alpha7 + IFN-γ + EP-blockade in microglia — that interaction is the genuinely novel output of this design, and the direction of the alpha7→PGE2→polarity link remains an inference, not an established fact.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.